EDP_305



NAME OF DRUG : EDP_305

ALSO KNOWN AS : EDP_305

LABORATORY : ENANTA

STATUS AND ADVANCEMENT

Type of drug : FXR agonist

Clinical trials advancement : Recruiting Phase 1

The drug got the Fast Track Status granted by the FDA

Estimated time to market : 107 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON EDP_305

SOME PUBLICATIONS RELATED WITH EDP_305

December 2017 : Targeting bile acids and lipotoxicity for NASH treatment

January 2017 : Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15 (necessity to monitor HCC risk with FXR agonists )

February 2013 : Dual actions of fibroblast growth factor 19 on lipid metabolism

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH EDP_305


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE